Non-Commissioned Officer (NCO) Immunity Master Practice Exam

Myasthenia gravis is classified as a Type II hypersensitivity reaction. This type of hypersensitivity is characterized by the immune system producing antibodies that target specific cells or tissues in the body, leading to their destruction or impaired function.

In the case of myasthenia gravis, the body produces antibodies against the acetylcholine receptor at the neuromuscular junction. This results in a blockade of nerve impulses, leading to muscle weakness and fatigue. The binding of these antibodies to the receptors prevents acetylcholine from effectively stimulating muscle contraction, ultimately affecting muscle function.

Type II hypersensitivity reactions typically involve IgG or IgM antibodies and are associated with the activation of the complement system and the cytotoxic effects mediated by these antibodies. In contrast, Type I reactions are primarily allergic responses governed by IgE, Type III involves immune complex deposition, and Type IV is mediated by T-cells rather than antibodies.

Understanding that myasthenia gravis falls under Type II hypersensitivity helps to clarify the mechanisms involved in the disorder and the role of the immune system in the pathophysiology of the disease.